---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009651"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:31:48.985492+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q1 2022: Cash $246.8M; BDC-1001 data on track for H2 2022

## Summary
- Cash, cash equivalents and marketable securities $246.8M at March 31, 2022; expected to fund operations into 2024.
- Collaboration revenue $0.8M from Genmab and Innovent partnerships; R&D expenses $18.4M vs $14.1M prior year.
- Loss from operations $23.9M vs $18.4M in Q1 2021, reflecting increased clinical and IND-enabling activities.
- Lead ISAC BDC-1001 monotherapy and OPDIVO combo dose escalation on track; data readout expected H2 2022.
- IND-enabling activities for CEA-targeted BDC-2034 and Dectin-2 agonist BDC-3042 progressing; BDC-3042 clinical start planned 2023.

## SEC filing metadata
- accession: 0000950170-22-009651
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017022009651/0000950170-22-009651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017022009651/bolt-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009651
- JSON: https://secwatch.observer/filing/0000950170-22-009651.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.